Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People
COVID-19
About this trial
This is an interventional prevention trial for COVID-19
Eligibility Criteria
Inclusion Criteria: Subjects aged 18 years and above on the day of enrollment; Had recent contact with an infected person, and the time of PCR sampling from a positive infected person, or the time of first contact with a positive infected person should not exceed 72 hours; The subjects can understand and voluntarily sign the informed consent form; Exclusion Criteria: Previous history of severe allergy or sensitivity to inhalation allergens; Women are breastfeeding, pregnant, or planning to become pregnant during the study period; Participated in clinical trials of SARS-CoV-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening; Subjects unable to cooperate with nasal spray inhalation; Body temperature at baseline (Day 0)>37.0℃; Had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis; The researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study; According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Sites / Locations
- Beijing Ditan Hospital, Capital Medical University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental Group A( non-continuous exposure to COVID-19)
Control Group A( non-continuous exposure to COVID-19)
Experimental Group B (continuous exposure to COVID-19)
Control Group B(continuous exposure to COVID-19)
1725 participants who were non-continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
575 participants who were non-continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day .
400 participants who were continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
200 participants who were continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.